BARDA awards $16 million to InBios to develop a point-of-care lateral flow diagnostic to detect Burkholderia pseudomallei, the bacteria that causes melioidosis.

InBios Receives FDA 510(k) Clearance for COVID-19 POC Antigen Detection Test

InBios Launches an In Vitro Diagnostic Test for Strongyloidiasis Providing Fast Results

InBios Awarded New Contract to Supply COVID-19 Tests

FDA Grants First Marketing Rights for Anthrax Point-of-Care Test to InBios

InBios Awarded Funding for Lyme Disease Diagnostic from HHS, Cohen Foundation

Rapid Antigen Tests Accurately Detect COVID Variants

Antigen Tests Accurately Detect COVID-19 Variants in Study

InBios Featured on NBC COVID-19 Update